<HTML>  
<HEAD>
  <meta name="Sperowider-ArchiveRoot" content="../../../../../../">
<meta name="Sperowider-DocRoot" content="../../../../">
<meta name="Sperowider-OriginalURL" content="http://www.erowid.org/archive/rhodium/chemistry/pcp/pcp_index.html">
<meta NAME="GENERATOR" CONTENT="Adobe PageMill 3.0 Mac">
  <meta HTTP-EQUIV="Content-Type" CONTENT="text/html; charset=iso-8859-1">
  <meta NAME="GENERATOR" CONTENT="Microsoft FrontPage Express 2.0">
  <TITLE>PCP synthesis and effects: table of contents</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff">

<P><CENTER><B><FONT SIZE="+4">Synthesis and Effects of PCP Analogs</FONT></B></CENTER></P>

<P><CENTER><B><FONT SIZE="+1">A review by <A HREF="mailto:beagle@mcafeemail.com">John
Q. Beagle</A></FONT></B></CENTER></P>

<P><CENTER> </CENTER></P>

<P><B><FONT COLOR="#dd0000" SIZE="+1">Disclaimer: </FONT></B>The
compounds described in this article are powerful drugs. As with
any drug, they should not be ingested without full understanding
of their potential effects. More so than other recreational drugs,
these compounds have the potential to produce dangerously disoriented
states of consciousness. The synthetic procedures presented here
are given for informational purposes only. Some of the steps presented
are potentially dangerous for novice or under equipped chemists,
and some of the compounds described are scheduled drugs, and therefore
illegal to manufacture without proper licensing.</P>

<P><CENTER><HR NOSHADE><BR>
<BR>
<B><STRONG><FONT SIZE="+3">Contents:</FONT></STRONG></B></CENTER></P>

<P><CENTER><U><FONT SIZE="+2"><BR>
Section I. Background information:</FONT></U><B><A HREF="sar.html#saramine"><HR WIDTH="85%"></A></B></CENTER></P>

<OL>
  <LI><A HREF="pcp_struc.html"><B><FONT SIZE="+1">Structure</FONT></B></A><B><FONT SIZE="+1"> of PCP and its analogs.<BR>
<BR>
  </FONT></B>
  <LI><A HREF="pcp_struc.html#othercpds"><B><FONT SIZE="+1">Structures
  of other compounds</FONT></B></A><B><FONT SIZE="+1"> with PCP-like
  effects.<BR>
<BR>
  </FONT></B>
  <LI><A HREF="effects.html"><B><FONT SIZE="+1">Historical background</FONT></B></A><B><FONT SIZE="+1"> of PCP.<BR>
<BR>
  </FONT></B>
  <LI><A HREF="effects.html#Pharmacology"><B><FONT SIZE="+1">Clinical
  use</FONT></B></A><B><FONT SIZE="+1"> and pharmacology.<BR>
<BR>
  </FONT></B>
  <LI><A HREF="effects.html#Illicit"><B><FONT SIZE="+1">Illicit
  use</FONT></B></A><B><FONT SIZE="+1"> and subjective effects.<BR>
<BR>
<BR>
  </FONT></B>
</OL>

<P><CENTER><U><FONT SIZE="+2">Section II. Known methods for synthesis
of PCP analogs:</FONT></U><B><A HREF="sar.html#saramine"><HR WIDTH="85%"><BR>
</A></B></CENTER></P>

<OL>
  <LI><A HREF="cn_synth.html#methods_rev"><B><FONT SIZE="+1">General
  overview</FONT></B></A><B><FONT SIZE="+1"> of methods:<BR>
<BR>
  </FONT></B>
  <LI><B><FONT SIZE="+1">Methods I-III. Commonly used routes:<BR>
<BR>
  </FONT></B>
  <OL>
    <LI><A HREF="cn_synth.html#scheme1"><B>Method I</B></A><B>: Use
    of nitrile intermediates such as PCC:</B>
    <OL>
      <LI><A HREF="cn_synth.html#scheme1">Overview</A> of the two steps
      in the reaction scheme.<BR>
      <LI><A HREF="cn_synth.html#pcc1">Step 1.</A> Synthesis of PCC-
      two possible methods.<BR>
      <LI><A HREF="cn_synth.html#genmeth1">Step 2.</A> Reaction of
      PCC with a Grignard reagent.<BR>
    </OL>
    <LI><A HREF="enam_synth.html#enamine"><B>Method II</B></A><B>:
    Use of enamine intermediates:</B>
    <OL>
      <LI><A HREF="enam_synth.html#enamine">General description</A>
      and reaction scheme.<BR>
      <LI><A HREF="enam_synth.html#pcpviaenamine">Details of the synthesis</A>
      of PCP via an enamine.<BR>
    </OL>
    <LI><A HREF="imine_synth.html"><B>Method III</B></A><B>: Use
    of imine intermediates:</B>
    <OL>
      <LI><A HREF="imine_synth.html">Overview</A> of reaction.<BR>
      <LI>Example: <A HREF="imine_synth.html#Examplepce">Synthesis
      of PCE</A>, the N-ethyl analog of PCP.<BR>
    </OL>
  </OL>
  <LI><A HREF="pca_synth.html"><B><FONT SIZE="+1">Methods IV-VI.</FONT></B></A><B><FONT SIZE="+1"> Use of PCA (1-phenyl-cyclohexylamine) intermediate:<BR>
<BR>
  </FONT></B>
  <OL>
    <LI><A HREF="pca_synth.html#SchemeIV"><B>Method IV</B></A><B>:
    Use of an azide intermediate:<BR>
    </B>PCA via PCOH (1-phenyl-1-cyclohexanol).<BR>
<BR>
    <LI><A HREF="pca_synth.html#ritter"><B>Method V</B></A><B>: The
    Ritter reaction:<BR>
    </B>PCA from PCOH or 1-phenylcyclohexene.<BR>
<BR>
    <LI><A HREF="pca_synth.html#scheme_vi"><B>Method VI</B></A><B>:
    Use of phenylacetonitrile:<BR>
    </B>Formation of the cyclohexane ring by alkylation and hydrolysis/rearrangement
    to PCA.<BR>
  </OL>
  <LI><A HREF="bzp_synth.html"><B><FONT SIZE="+1">Method VII</FONT></B></A><B><FONT SIZE="+1">: Use of N-benzoyl piperidine:<BR>
  </FONT></B>Reaction with organometallic derivative of 1,5-dibromopentane
  to produce PCP.<BR>
</OL>

<P><CENTER><A HREF="sar.html#saramine"><B><BR>
<BR>
</B></A><U><FONT SIZE="+2">Section III. Synthesis of PCP precursors:</FONT></U><B><A HREF="sar.html#saramine"><HR WIDTH="85%"></A></B><BR>
</CENTER></P>

<OL>
  <LI><A HREF="precurs_synth.html"><B><FONT SIZE="+1">Cyclohexanone</FONT></B></A><B><FONT SIZE="+1">:<BR>
  </FONT></B>by the oxidation of cyclohexanol.<BR>
<BR>
  <LI><A HREF="precurs_synth.html"><B><FONT SIZE="+1">Piperidine:</FONT></B></A><BR>
  by reduction of pyridine.<BR>
</OL>

<P><CENTER><A HREF="sar.html#saramine"><B><BR>
</B></A><U><FONT SIZE="+2">Section IV. Synthesis of ketamine:</FONT></U><B><A HREF="sar.html#saramine"><HR WIDTH="85%"></A></B><BR>
</CENTER></P>

<OL>
  <LI><A HREF="ketamine.html"><B><FONT SIZE="+1">Overview of synthesis:<BR>
<BR>
  </FONT></B></A>
  <LI><A HREF="ketamine.html#ketaminerxns"><B><FONT SIZE="+1">Detailed
  procedure:</FONT></B></A><BR>
</OL>

<P><CENTER><A HREF="sar.html#saramine"><B><BR>
<BR>
</B></A><U><FONT SIZE="+2">Section V. Structure-Activity Relationships
(SAR) of PCP analogs:</FONT></U><B><A HREF="sar.html#saramine"><HR WIDTH="85%"></A></B><BR>
<BR>
<BR>
</CENTER></P>

<OL>
  <LI><A HREF="sar.html"><B><FONT SIZE="+1">Background</FONT></B></A><FONT SIZE="+1">.</FONT><BR>
  biological evaluation of analogs.<BR>
<BR>
<BR>
  <LI><A HREF="sar.html#sarmods"><B><FONT SIZE="+1">Structural
  modifications of PCP</FONT></B></A><FONT SIZE="+1">:<BR>
<BR>
  </FONT>
  <OL>
    <LI><A HREF="sar.html#saramine"><B>Alterations to the piperidine
    ring</B></A>
    <OL>
      <LI>Non cyclic alkyl substituents.
      <LI>Cyclic alkylamines.<BR>
<BR>
    </OL>
    <LI><A HREF="sar.html#sarphenyl"><B>Alterations to the aromatic
    (phenyl) ring:</B></A>
    <OL>
      <LI>Addition of substituents to the phenyl ring.
      <LI>Replacements of phenyl by other aromatic rings.<BR>
<BR>
    </OL>
    <LI><A HREF="sar.html#sarcyclo"><B>Alterations to the cyclohexane
    ring:</B></A>
    <OL>
      <LI>Changes in ring size.
      <LI>Addition of substituents.<BR>
<BR>
    </OL>
  </OL>
</OL>

<P><CENTER><A HREF="sar.html#saramine"><B><BR>
</B></A><U><FONT SIZE="+2">Section VI. Recent Research on PCP
analogs:</FONT></U><B><A HREF="sar.html#saramine"><HR WIDTH="85%"></A></B><BR>
<BR>
</CENTER></P>

<OL>
  <LI><A HREF="research_refs.html"><B><FONT SIZE="+1">Overview<BR>
<BR>
  </FONT></B></A>
  <LI><A HREF="research_refs.html#dopa"><B><FONT SIZE="+1">Dopamine
  receptors:</FONT></B></A><BR>
  analogs that bind to a novel site on the dopamine transporter.<BR>
<BR>
  <LI><A HREF="research_refs.html#sigma"><B><FONT SIZE="+1">Sigma
  receptors</FONT></B></A>:<BR>
  relationship to PCP pharmacology.<BR>
<BR>
  <LI><A HREF="research_refs.html#opiate"><B><FONT SIZE="+1">Opiate
  receptors</FONT></B></A>:<BR>
  analogs with analgesic potential.<BR>
<BR>
  <LI><A HREF="research_refs.html#References"><B><U><FONT SIZE="+1">References</FONT></U></B></A>
</OL>

</BODY>
</HTML>
